What Is Polmacoxib?
Polmacoxib is a selective COX‑2 inhibitor NSAID, also with mild carbonic anhydrase inhibition. Unlike non-selective NSAIDs, it’s designed to reduce pain and inflammation while minimizing gastrointestinal side effects
Approved Uses
A). Primary – Osteoarthritis of the hip and knee: relieves pain, stiffness, and improves joint function
B). Other potential indications – Rheumatoid arthritis, ankylosing spondylitis, postoperative acute pain (e.g. dental, surgical), and menstrual pain
Mechanism of Action
a). COX‑2 suppression lowers pro‑inflammatory prostaglandins, reducing pain and swelling.
b). Carbonic anhydrase uptake via red blood cells enhances delivery to inflamed joints, maintaining low systemic exposure
Dosage & Administration
a). Typical dose: 2mg orally once daily with meals; do not exceed 2mg/day
b). Pharmacokinetics: T_max ~5–6 hours, half‑life ~130 hours, primarily fecal excretion
Efficacy & Clinical Trials
a). Demonstrated efficacy comparable to celecoxib in reducing WOMAC pain scores in Phase III osteoarthritis trials.
b). Higher doses (e.g. 4–8mg) showed dose-dependent benefits; 2mg is preferred for safety and effectiveness .
Side Effects & Warnings
a). Common: headache, nausea, dyspepsia, dizziness, abdominal discomfort, diarrhea, peripheral edema
b). Serious but rare: gastrointestinal bleeding/ulcers; cardiovascular risks (e.g. hypertension, edema); hepatotoxicity/renal issues .
c). Contraindications/caution in: heart/kidney/liver disease, uncontrolled hypertension, peptic ulcer, NSAID allergy, third-trimester pregnancy, breastfeeding .
d). Drug interactions: anticoagulants (e.g. warfarin), ACE inhibitors, diuretics, lithium, methotrexate, corticosteroids, SSRIs .
e). Advice: take with food, avoid alcohol, use caution if driving (due to dizziness) .
Regulatory Approval
In India, DCGI approved 2mg polmacoxib (Acelex) on February 14, 2023 for idiopathic primary osteoarthritis of hip and knee.
Elkos Healthcare & Polmacoxib 2mg
Elkos Healthcare is a WHO‑GMP & ISO 9001 certified pharma company in Haryana, offering capsules — including polmacoxib 2mg — via PCD pharma franchise and third-party manufacturing. Their Fawn Incor/Coxpol‑2 capsules are indicated for:
a). Osteoarthritis
b). Rheumatoid arthritis
c). Postoperative pain relief
Contact Elkos Healthcare
contact number: +91-96930-22222
Website: www.elkosgroup.in
Email: elkos7777@gmail.com
Address:Plot NO.246 HSIIDC Industrial EstateAlipur, Barwala, Panchkula-134118 Haryana, India.
Final Thoughts
Polmacoxib 2mg offers targeted pain relief with a more favorable GI profile compared to non-selective NSAIDs. However, like all NSAIDs, it carries cardiovascular and renal risks—so use only as prescribed. Elkos Healthcare supplies quality polmacoxib capsules via their manufacturing and franchise channels.